Haley Ellis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haley Ellis has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Nabeel Bardeesy
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts
40 shared publications - Eranga Roshan Balasooriya
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts
35 shared publications - Ryan B. Corcoran
Division of Hematology-Oncology, Massachusetts General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA
35 shared publications - Vanessa Silva Silveira
Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, USA; Department of Medicine, Harvard Medical School, Boston, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, USA
35 shared publications - Yuanli Zhen
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts
35 shared publications - Bryanna L. Norden
Massachusetts General Hospital Cancer Center Department of Medicine Harvard Medical School Boston MA USA
34 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Fig. S1, S2, S3, S4, S5 from MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
Supplementary Figures S1, S2, S3, S4, S5 with legends
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFig. S1, S2, S3, S4, S5 from MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
Supplementary Figures S1, S2, S3, S4, S5 with legends
- Top Cited Papers
- 20 January 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (6) , 798-812
Mechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib
- 20 January 2026
- Published by Elsevier in Annals of Oncology
- Vol. 37 (6) , 798-812
Top Cited PapersMechanisms of clinical resistance to selective FGFR2 inhibition by lirafugratinib
- Open Access
- 29 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 925-937
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
Purpose: Mutant IDH1 (mIDH1) defines a therapeutically targetable subtype of intrahepatic cholangiocarcinoma (ICC), with the mIDH1 inhibitor ivosidenib approved for advanced disease. A subset of patients experiences prolonged disease stabilization; however, the molecular basis for eventual progression remains poorly defined. Experimental Design: We performed molecular profiling of matched baseline and postprogression circulating tumor DNA (ctDNA) samples from patients with mIDH1 ICC enrolled in the ClarIDHy phase III trial. Functional studies were conducted to characterize candidate resistance mechanisms. Results: Longitudinal ctDNA analysis of 18 patients treated with ivosidenib for >6 months revealed emergent genomic alterations in multiple cases. Acquired mutations in mitogen-activated protein kinase (MAPK) pathway genes (KRAS, NRAS, MAP2K1, NF1) were identified in five cases, with instances of concurrent alterations and/or high variant allele fractions (VAF). Additional candidate resistance events included a secondary IDH1 mutation and a hotspot IDH2 mutation, detected at low VAF in the same patient. Functional studies showed that these IDH mutations conferred sustained 2-hydroxyglutarate production and ivosidenib resistance, whereas MAPK activation blunted gene expression induced by ivosidenib plus IFNγ, a key therapeutic output of mIDH1 inhibition. In parallel, baseline ctDNA profiling of 81 patients revealed that ARID1A mutations and elevated mIDH1 VAF were associated with reduced clinical benefit. Conclusions: MAPK pathway alterations represent a recurrent mechanism of resistance to mIDH1 inhibition in ICC, whereas emergent IDH1/IDH2 mutations appear infrequent. Functional data suggest that MAPK-mediated resistance may involve impaired IFN signaling. These results support MAPK-directed combination strategies and highlight the utility of ctDNA profiling to identify predictive and resistance biomarkers in mIDH1-driven ICC.
- 29 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (5) , 925-937
Open AccessMAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response
Purpose: Mutant IDH1 (mIDH1) defines a therapeutically targetable subtype of intrahepatic cholangiocarcinoma (ICC), with the mIDH1 inhibitor ivosidenib approved for advanced disease. A subset of patients experiences prolonged disease stabilization; however, the molecular basis for eventual progression remains poorly defined. Experimental Design: We performed molecular profiling of matched baseline and postprogression circulating tumor DNA (ctDNA) samples from patients with mIDH1 ICC enrolled in the ClarIDHy phase III trial. Functional studies were conducted to characterize candidate resistance mechanisms. Results: Longitudinal ctDNA analysis of 18 patients treated with ivosidenib for >6 months revealed emergent genomic alterations in multiple cases. Acquired mutations in mitogen-activated protein kinase (MAPK) pathway genes (KRAS, NRAS, MAP2K1, NF1) were identified in five cases, with instances of concurrent alterations and/or high variant allele fractions (VAF). Additional candidate resistance events included a secondary IDH1 mutation and a hotspot IDH2 mutation, detected at low VAF in the same patient. Functional studies showed that these IDH mutations conferred sustained 2-hydroxyglutarate production and ivosidenib resistance, whereas MAPK activation blunted gene expression induced by ivosidenib plus IFNγ, a key therapeutic output of mIDH1 inhibition. In parallel, baseline ctDNA profiling of 81 patients revealed that ARID1A mutations and elevated mIDH1 VAF were associated with reduced clinical benefit. Conclusions: MAPK pathway alterations represent a recurrent mechanism of resistance to mIDH1 inhibition in ICC, whereas emergent IDH1/IDH2 mutations appear infrequent. Functional data suggest that MAPK-mediated resistance may involve impaired IFN signaling. These results support MAPK-directed combination strategies and highlight the utility of ctDNA profiling to identify predictive and resistance biomarkers in mIDH1-driven ICC.
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 1
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 1
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 7
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 7
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 5
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 5
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 3
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 3
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 6
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 6
- Open Access
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 2
- 4 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
Excel file containing all data corresponding to Figure 2